Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2024.1473858 Oncology Original Research Risk factors associated with lymph node metastasis in papillary thyroid cancer: a retrospective analysis based on 2,428 cases Yu Kejie Wu Xianjiang Dai Lei Le Qi Xie Yue Wang Yingchun Zhang Weidong * Department of Thyroid Surgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, China

Edited by: Erivelto Martinho Volpi, Hospital Alemão Oswaldo Cruz, Brazil

Reviewed by: Khawla S. Al-Kuraya, King Faisal Specialist Hospital and Research Centre, Saudi Arabia

Peisong Wang, The 1st Hospital of Jilin University, China

*Correspondence: Weidong Zhang, zhangweidongqq11@163.com

06 11 2024 2024 14 1473858 31 07 2024 22 10 2024 Copyright © 2024 Yu, Wu, Dai, Le, Xie, Wang and Zhang 2024 Yu, Wu, Dai, Le, Xie, Wang and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

Papillary thyroid cancer (PTC) with lymph node metastasis (LNM) is associated with an increased risk of postoperative recurrence. Understanding the clinical characteristics of PTC patients can help surgeons assess the likelihood of LNM. This study aims to identify risk factors for LNM in PTC patients.

 Methods

We retrospectively analyzed clinical data from 2,428 patients diagnosed with PTC who underwent initial thyroid surgery in our single center. Risk factors related to central lymph node metastasis (CLNM), lateral lymph node metastasis (LLNM), and skip metastasis were investigated by univariate and multivariate binary logistic regression analyses.

 Results

Univariate analysis revealed that the following factors were associated with an increased likelihood of CLNM (P<0.05): male gender, age < 45 years, maximal axial diameter (MAD) > 1 cm, body mass index (BMI) ≥ 28 kg/m² and multifocality. Univariate analysis also revealed that patients with age < 45 years, MAD > 1 cm, BMI ≥ 28 kg/m², multifocality, and CLNM demonstrated a higher propensity for LLNM (P<0.05). Lower pole tumors were more likely to have CLNM than upper pole tumors, while upper pole tumors were more prone to present LLNM (P<0.05) and skip metastasis (P<0.05). Multivariable binary logistic regression analysis identified that gender (odds ratio [OR], 1.732; 95% CI, 2.113–2.577; P < 0.001), age (OR, 1.905; 95% CI, 1.596–2.273; P < 0.001), MAD (OR, 4.639; 95% CI, 3.639–5.913; P < 0.001), and multifocality (OR, 1.860; 95% CI, 1.453–2.381; P < 0.001) were independent risk factors for CLNM and MAD (OR, 5.289; 95% CI, 3.777–7.404; P<0.001), multifocality (OR, 1.858; 95% CI, 1.248–2.766; P=0.002), and CLNM (OR, 5.030; 95% CI, 3.347–7.561; P<0.001) for LLNM.

 Conclusion

Despite the overall postoperative recurrence rate in PTC patients is low, identifying risk factors such as male gender, age < 45 years, MAD > 1 cm, multifocality, and CLNM can help predict LNM. In specific cases, selective lymphadenectomy in the central or lateral neck area may be warranted.

 papillary thyroid cancer central lymph node metastasis lateral lymph node metastasis skip metastasis risk factor section-in-acceptance Head and Neck Cancer Introduction

In recent years, the global incidence of thyroid cancer has seen a steady increase, making it the most prevalent malignant tumor of the endocrine system (1). Notably, the number of new thyroid cancer cases worldwide rose from approximately 122,800 in 2000 to 586,202 by 2020 (2, 3). Among malignant thyroid tumors, over 90% are classified as papillary thyroid cancer (PTC), which primarily spreads through lymph node metastasis (LNM) (4, 5). LNM typically begins in the central region before progressing to the lateral neck area (6), although isolated cases of skip metastasis (lateral neck metastasis without central involvement) also occur (7, 8).Research has highlighted the correlation between LNM in the neck and an elevated risk of post-surgery recurrence (9). Additionally, LNM in the lateral neck region often indicates a poor prognosis and an increased likelihood of requiring additional surgical intervention (10, 11).

However, controversy surrounds the routine use of central lymph node dissection (CLND) during PTC surgery due to the associated risks, including laryngeal nerve injury and hypoparathyroidism (12, 13). The American Thyroid Association (ATA) recommends therapeutic CLND for patients with clinical evidence of lymph node involvement (14). Identifying risk factors associated with LNM is crucial for surgeons to accurately assess the likelihood of lymph node involvement in patients. This knowledge enables more precise surgical planning and informed decision-making regarding neck lymph node dissection (LND) (15, 16). Despite ongoing debate in clinical practice, this retrospective study specifically examines the correlations between various clinical characteristics and central lymph node metastasis (CLNM), lateral lymph node metastasis (LLNM), and skip metastasis. The findings aim to facilitate the identification of risk factors for LNM and provide guidance for clinical decision-making.

 Materials and methods Patients and clinical data collection

We conducted a retrospective analysis of 2,428 patients diagnosed with PTC who underwent their initial thyroid surgery at Ningbo NO. 2 Hospital between January 2023 and December 2023. The study included patients who met the following criteria:

Underwent their first thyroid surgery

Possessed comprehensive clinical data

Received postoperative pathology confirmation of PTC without concurrent other types of thyroid cancer

Clinical and pathological characteristics, including gender, age, maximal axial diameter (MAD), body mass index (BMI), multifocality, Hashimoto’s thyroiditis (HT), CLNM, LLNM, and tumor location, were extracted from electronic medical records and the Ningbo Resident Health Big Data Archive. Continuous variables (age, MAD, BMI) were categorized based on predefined cut-off points:

Age: ≥45 years and <45 years

MAD: >1 cm and ≤1 cm

BMI: ≥28 kg/m² (obese) and <28 kg/m² (non-obese)

We categorized tumor location as upper pole, middle pole, and lower pole (excluding scattered and isthmic tumors). The diagnosis of HT and LNM relied on postoperative histopathological examination of tissue samples.

 Statistical analysis

Data management and statistical analyses were performed using IBM SPSS Statistics, Version 27.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were presented as frequencies and percentages. Univariate analysis utilized the chi-square test, with P < 0.05 considered statistically significant. Variables identified through univariate analysis underwent multivariate binary logistic regression to assess the impact of potential risk factors. Results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). A significance level of P<0.05 was considered statistically significant.

 Results

This retrospective analysis included 2,428 patients diagnosed with PTC, of whom 944 (38.88%) exhibited CLNM and 177 (7.23%) presented with LLNM.

CLNM

Patients were stratified into the CLNM+ group (944 patients) and the CLNM- group (1,484 patients). Univariate analysis revealed significant associations between CLNM and gender (P < 0.001), age (P < 0.001), MAD (P < 0.001), BMI (P < 0.001), multifocality (P < 0.001), and HT (P = 0.038) ( Table 1 ). Male patients, patients younger than 45 years, patients with MAD > 1 cm, BMI ≥ 28 kg/m², and multifocality were more likely to have CLNM, whereas patients with HT had a lower risk. Multivariable binary logistic regression analysis showed that male gender (OR, 1.732; 95% CI, 2.113–2.577; P < 0.001), age < 45 years (OR, 1.905; 95% CI, 1.596–2.273; P < 0.001), MAD > 1 cm (OR, 4.639; 95% CI, 3.639–5.913; P < 0.001), and multifocality (OR, 1.860; 95% CI, 1.453–2.381; P < 0.001) were independent risk factors for CLNM ( Figure 1 ). HT (OR, 0.922; 95% CI, 0.731–1.161; P = 0.922) and BMI (OR, 1.089; 95% CI, 0.829–1.432; P = 0.539) showed weaker associations with CLNM. The Hosmer and Lemeshow Test (P = 0.792) indicated a good fit for the regression model.

Univariate analysis of the clinical and pathological factors associated with CLNM.

CLNM p-value
+ (n=944) - (n=1484)
Gender
 Male 639 338 301 <0.001
 Female 1789 606 1183
Age (years)
 <45 1034 495 539 <0.001
 ≥45 1394 449 945
MAD (cm)
 ≤1 2039 673 1366 <0.001
 >1 389 271 118
BMI (kg/m2)
 ≥28 284 136 148 <0.001
 <28 2144 808 1336
Multifocality
 Yes 337 172 165 <0.001
 No 2091 772 1319
HT
 Yes 443 153 290 0.038
 No 1985 791 1194

CLNM, Central lymph node metastasis; MAD, Maximal axial diameter; BMI, Body mass index; HT, Hashimoto’s thyroiditis.

Multivariate logistic regression analysis of central lymph node metastasis.

 LLNM

Patients were also categorized into the LLNM+ group (177 patients) and the LLNM- group (2,251 patients). Univariate analysis identified significant correlations between LLNM and age (P = 0.002), MAD (P < 0.001), BMI (P = 0.003), multifocality (P < 0.001), and CLNM (P < 0.001) ( Table 2 ). HT (P = 0.794) and gender (P = 0.136) showed no association with LLNM. Patients younger than 45 years, with MAD > 1 cm, BMI ≥ 28 kg/m², multifocality, and CLNM exhibited a higher likelihood of]LLNM. Multivariate binary logistic regression analysis indicated that MAD > 1 cm (OR, 5.289; 95% CI, 3.777–7.404; P < 0.001), multifocality (OR, 1.858; 95% CI, 1.248–2.766; P = 0.002), and CLNM (OR, 5.030; 95% CI, 3.347–7.561; P < 0.001) were independent risk factors for LLNM ( Figure 2 ). Age (OR, 1.189; 95% CI, 0.851–1.662; P = 0.310) and BMI (OR, 1.309; 95% CI, 0.840–2.039; P = 0.233) showed weaker associations with LLNM. The Hosmer and Lemeshow Test (P = 0.648) indicated a good fit for the regression model.

Univariate analysis of the clinical and pathological factors associated with LLNM.

LLNM p-value
+ (n=177) - (n=2251)
Gender
 Male 639 55 584 0.136
 Female 1789 122 1667
Age (years)
 <45 1034 95 939 0.002
 ≥45 1394 82 1312
MAD (cm)
 ≤1 2039 78 1961 <0.001
 >1 389 99 290
BMI (kg/m2)
 ≥28 284 33 251 0.003
 <28 2144 144 2000
Multifocality
 Yes 337 42 295 <0.001
 No 2091 135 1956
HT
 Yes 443 31 412 0.794
 No 1985 146 1839
CLNM
 + 944 147 797 <0.001
 - 1484 33 1451

CLNM, Central lymph node metastasis; LLNM, Lateral lymph node metastasis; MAD, Maximal axial diameter; BMI, Body mass index; HT, Hashimoto’s thyroiditis.

Multivariate logistic regression analysis of lateral lymph node metastasis.

 Tumor location and LNM

Tumor location was categorized as upper, middle, and lower (excluding multi-site distribution tumors and isthmic tumors, with a total of 2,020 patients included). Chi-square tests and multiple comparisons ( Table 3 ) indicated that lower pole tumors were more likely to have CLNM compared to upper pole tumors (P = 0.011), while upper pole tumors were more prone to LLNM than lower pole tumors (P = 0.001). Due to multiple comparisons among the three groups, a P-value < 0.0167 was considered statistically significant. In a subset of 149 patients with LLNM ( Table 4 ), upper pole tumors showed a higher propensity for skip metastasis (LLNM without CLNM) compared to those located in the middle (P = 0.007) or lower pole (P = 0.016).

Univariate analysis of the tumor location associated with CLNM and LLNM.

CLNM p-value LLNM p-value
+ - + -
Location
 Upper 195 378 0.021 59 514 0.004
 Middle 237 431 45 623
 Lower 318 461 44 735
multiple comparison
 Upper 195 378 0.594 59 514 0.024
 Middle 237 431 45 623
 Upper 195 378 0.011 59 514 0.001
 Lower 318 461 44 735
 Middle 237 431 0.037 45 623 0.390
 Lower 318 461 44 735

CLNM, Central lymph node metastasis; LLNM, Lateral lymph node metastasis.

Univariate analysis of the tumor location in relation to PTC with LLNM but no CLNM.

CLNM p-value
+ -
Location
 Upper 39 20 0.006
 Middle 40 5
 Lower 39 6
multiple comparison
 Upper 39 20 0.007
 Middle 40 5
 Upper 39 20 0.016
 Lower 39 6
 Middle 40 5 0.748
 Lower 39 6

CLNM, Central lymph node metastasis; LLNM, Lateral lymph node metastasis.

 Discussion

The prognosis for PTC patients is generally favorable, with a low recurrence rate. However, conflicting studies exist regarding the impact of LNM on survival. Some suggest that PTC patients with LNM at initial surgery or experiencing LNM recurrence have a lower survival rate (17–20), while others find no significant effect (21, 22). In most countries, routine lateral lymph node dissection (LLND) occurs only when clear evidence of LNM is present. Prophylactic lymphadenectomy is not recommended for patients without preoperatively detected cervical LNM. At our hospital, CLND is routinely performed for most PTC patients. LLND is only performed when LLNM is confirmed by preoperative or intraoperative pathological examination. Despite controversy over the prognostic significance of lymph node involvement at initial surgery, regional lymph node recurrence remains a concern (23, 24). Considering patients’ quality of life, the presence of LNM plays a crucial role in mitigating subsequent surgical interventions.

Preoperative assessment of LNM in PTC relies on color Doppler ultrasound (US) and neck computerized tomography (CT). However, US sensitivity for detecting LNM is only 60-70% (25, 26), leading to challenges in distinguishing reactive lymphadenopathy from true metastatic disease. Enhanced CT scans can identify calcified metastatic nodes but have limitations in detecting non-calcified nodes (27). Clinicians still struggle to determine the need for LND before PTC surgery.

Our study analyzed risk factors associated with CLNM, LLNM, and skip metastasis. We found that male gender, age <45 years, MAD >1 cm, BMI ≥28 kg/m², and multifocality correlated with CLNM. Interestingly, HT emerged as a protective factor for CLNM. Among these factors, male gender, age <45 years, and MAD >1cm emerged as independent risk factors. While previous studies also linked age <45, male gender, tumor size, and multifocality to CLNM (28–30). Some studies indicated HT as a risk factor for CLNM (28), but others suggested potential protective mechanisms of HT (31). The specific impact of HT remains unclear. Our study showed a reduction in the risk of CLNM occurrence in HT patients. Close monitoring for CLNM is recommended in patients with these independent risk factors, considering prophylactic CLND.

The variables associated with the incidence of LLNM included age < 45 years, MAD > 1 cm, BMI ≥ 28 kg/m², multifocality, and CLNM. Meanwhile, MAD > 1 cm, multifocality, and CLNM established as independent risk factors for LLNM. This study also revealed that tumors situated in the upper pole exhibited a higher propensity for developing LLNM and skip metastasis, while those located in the lower pole were more likely to develop CLNM. A meta-analysis suggested that CLNM, tumor size, multifocality, male gender, and tumor location were independent risk factors for LLNM (32), which aligns with the results of this study. Zhao et al. (33) also identified a tumor diameter > 1 cm and CLNM as independent risk factors for LLNM, and found that upper pole tumors had a higher propensity for skip metastasis, consistent with our findings. Upper pole tumors are more likely to demonstrate skip metastasis, potentially due to preferential dissemination of the tumor via the superior thyroid artery to the lateral lymph nodes rather than through the lymphatic vessels (34).We recommend that PTC patients with preoperative examinations indicating tumor size > 1 cm, multiple lesions, or evident CLNM found intraoperatively, should be carefully evaluated for the potential presence of LLNM. These individuals may undergo lateral lymph node (LLN) biopsy during surgery, and if deemed necessary, LLND may be performed. For tumors located at the upper pole, even without apparent CLNM, monitoring of LLN should still be conducted.

Furthermore, BMI was a key variable of interest in this investigation. Given the observed higher incidence of LNM among obese patients in clinical practice, we conducted a comparison between obese patients (BMI ≥ 28 kg/m²) and non-obese patients (BMI < 28 kg/m²). Univariate analysis revealed that obese patients exhibited a greater likelihood of CLNM and LLNM compared to non-obese patients. However, multivariate analysis indicated that BMI did not independently contribute to the risk of LNM. The relationship between obesity and LNM remains ambiguous, with limited relevant studies available (35). Inclusion of BMI in the analysis provided clinicians valuable insights.

Although numerous studies have investigated the risk factors for CLNM or LLNM, the conclusion is still controversial. Our study conducted a comprehensive statistical comparison of the risk factors associated with CLNM, LLNM, and skip metastasis, offering a more thorough analysis. LNM significantly contributes to postoperative recurrence and poor prognosis in patients with PTC, potentially necessitating secondary surgery and impacting patients’ psychological well-being and quality of life. However, performing LND on all patients may increase the incidence of unnecessary surgical complications such as recurrent laryngeal nerve injury, hypoparathyroidism, and chylothorax. Consequently, preoperatively evaluating LNM and determining whether to perform LND has remained a challenging issue for surgeons. Some studies have indicated that prophylactic CLND can reduce local recurrence rates in high-risk patients (36, 37), while therapeutic LLND should be considered for those with suspected or confirmed LLNM preoperatively (14). US and CT imaging have inherent limitations in distinguishing between different types of lymph nodes, and biopsy is not routinely performed as an examination method. When combined with an analysis of LNM risk factors, these imaging methods can enhance effectiveness and accuracy in evaluating lymph nodes, reducing the likelihood of misdiagnosis, ultimately diminishing the risk of recurrence, and enhancing patient quality of life.

Our study has certain limitations. Firstly, it is a retrospective study, and despite the large sample size, the results may be subject to bias. Secondly, there is a possibility of occult cancer or LNM that cannot be diagnosed through pathology. Thirdly, due to the limited number of skip metastasis cases, we did not conduct a multivariate analysis in this subgroup. Therefore, we hope that future research will involve a multi-center prospective study to more accurately analyze the risk factors for PTC patients.

 Conclusion

Despite the overall postoperative recurrence rate in PTC patients is low, identifying risk factors such as male gender, age < 45 years, MAD > 1 cm, multifocality, and CLNM can help predict LNM. In specific cases, selective lymphadenectomy in the central or lateral neck area may be warranted.

 Data availability statement

The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding author.

 Ethics statement

The studies involving humans were approved by Human Research Ethics Committee of Ningbo No.2 Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The retrospective nature of the study, approved by the Human Research Ethics Committee of Ningbo No.2 Hospital, obviated the need for informed consent from the subjects.

 Author contributions

KY: Formal analysis, Methodology, Writing – original draft, Writing – review & editing, Conceptualization. XW: Funding acquisition, Supervision, Writing – review & editing, Methodology. LD: Supervision, Writing – review & editing, Visualization. QL: Data curation, Writing – review & editing. YX: Data curation, Writing – review & editing. YW: Data curation, Writing – review & editing. WZ: Formal analysis, Funding acquisition, Writing – review & editing.

 Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study received funds from Ningbo Leading Medical and Health Discipline (grant no. 2022-F18), Ningbo Public Service Technology Foundation (grant no. 2023S139) and Zhu Xiushan Talent Award Fund of Ningbo No.2 Hospital (grant no. 2023HMYQ04) to cover publication costs.

 Acknowledgments

We gratefully acknowledge Xianjiang Wu, Director of the Thyroid Surgery Center, for providing us with the data platform, and Dr. Qiuda Zheng (Queensland Alliance for Environmental Health Sciences, The University of Queensland, Brisbane, Queensland, Australia) for offering valuable insights during the paper composition.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2024.1473858/full#supplementary-material

References Cabanillas ME McFadden DG Durante C . Thyroid cancer. Lancet. (2016) 388:2783–95. doi: 10.1016/S0140-6736(16)30172-6 Parkin DM Bray F Ferlay J Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. (2001) 94:153–6. doi: 10.1002/(ISSN)1097-0215 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 Lee SH Roh J-L Gong G Cho K-J Choi S-H Nam SY . Risk factors for recurrence after treatment of N1b papillary thyroid carcinoma. Ann Surg. (2019) 269:966–71. doi: 10.1097/SLA.0000000000002710 Eskander A Merdad M Freeman JL Witterick IJ . Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: A systematic review and meta-analysis. Thyroid. (2013) 23:583–92. doi: 10.1089/thy.2012.0493 Sivanandan R Soo KC . Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg. (2001) 88:1241–4. doi: 10.1046/j.0007-1323.2001.01843.x Lim YC Koo BS . Predictive factors of skip metastases to lateral neck compartment leaping central neck compartment in papillary thyroid carcinoma. Oral Oncol. (2012) 48:262–5. doi: 10.1016/j.oraloncology.2011.10.006 Lei J Zhong J Jiang K Li Z Gong R Zhu J . Skip lateral lymph node metastasis leaping over the central neck compartment in papillary thyroid carcinoma. Oncotarget. (2017) 8:27022–33. doi: 10.18632/oncotarget.15388 Leboulleux S Rubino C Baudin E Caillou B Hartl DM Bidart J-M . Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis. J Clin Endocrinol Metab. (2005) 90:5723–9. doi: 10.1210/jc.2005-0285 Ito Y Kudo T Takamura Y Kobayashi K Miya A Miyauchi A . Lymph node recurrence in patients with N1b papillary thyroid carcinoma who underwent unilateral therapeutic modified radical neck dissection. World J Surg. (2011) 36:593–7. doi: 10.1007/s00268-011-1391-1 Baek SK Jung KY Kang SM Kwon SY Woo JS Cho SH . Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. (2010) 20:147–52. doi: 10.1089/thy.2008.0243 Ahn S-H Hong HJ Kwon SY Kwon KH Roh J-L Ryu J . Guidelines for the surgical management of laryngeal cancer: Korean society of thyroid-head and neck surgery. Clin Exp Otorhinolaryngol. (2017) 10:1–43. doi: 10.21053/ceo.2016.01389 Calò PG Pisano G Medas F Marcialis J Gordini L Erdas E . Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World J Surg Oncol. (2014) 12:152. doi: 10.1186/1477-7819-12-152 Haugen BR Alexander EK Bible KC Doherty GM Mandel SJ Nikiforov YE . 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. (2016) 26:1–133. doi: 10.1089/thy.2015.0020 McDow AD Pitt SC . Extent of surgery for low-risk differentiated thyroid cancer. Surg Clinics North America. (2019) 99:599–610. doi: 10.1016/j.suc.2019.04.003 Krajewska J Kukulska A Oczko-Wojciechowska M Kotecka-Blicharz A Drosik-Rutowicz K Haras-Gil M . Early diagnosis of low-risk papillary thyroid cancer results rather in overtreatment than a better survival. Front Endocrinol. (2020) 11. doi: 10.3389/fendo.2020.571421 Beasley NJ Lee J Eski S Walfish P Witterick I Freeman JL . Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg. (2002) 128:825–8. doi: 10.1001/archotol.128.7.825 Sugitani I Fujimoto Y Yamamoto N . Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control. Surgery. (2008) 143:35–42. doi: 10.1016/j.surg.2007.06.011 Zhou L Li Q Chen S Huang Y Wei W Zhang C . Synergic effects of histology subtype, lymph node metastasis, and distant metastasis on prognosis in differentiated thyroid carcinoma using the SEER database. Gland Surg. (2020) 9:907–18. doi: 10.21037/gs-20-273 Adam MA Pura J Goffredo P Dinan MA Reed SD Scheri RP . Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. (2015) 33:2370–5. doi: 10.1200/JCO.2014.59.8391 Sancho JJ Lennard TW Paunovic I Triponez F Sitges-Serra A . Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. (2014) 399:155–63. doi: 10.1007/s00423-013-1152-8 Kim SK Woo JW Lee JH Park I Choe JH Kim JH . Prophylactic central neck dissection might not be necessary in papillary thyroid carcinoma: analysis of 11,569 cases from a single institution. J Am Coll Surg. (2016) 222:853–64. doi: 10.1016/j.jamcollsurg.2016.02.001 Lee J Song Y Soh EY . Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma. J Korean Med Sci. (2014) 29:48-52. doi: 10.3346/jkms.2014.29.1.48 Randolph GW Duh QY Heller KS LiVolsi VA Mandel SJ Steward DL . The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. (2012) 22:1144–52. doi: 10.1089/thy.2012.0043 Eun NL Son EJ Kim JA Gweon HM Kang JH Youk JH . Comparison of the diagnostic performances of ultrasonography, CT and fine needle aspiration cytology for the prediction of lymph node metastasis in patients with lymph node dissection of papillary thyroid carcinoma: A retrospective cohort study. Int J Surg. (2018) 51:145–50. doi: 10.1016/j.ijsu.2017.12.036 Wu LM Gu HY Qu XH Zheng J Zhang W Yin Y . The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: A meta-analysis. Eur J Radiol. (2012) 81:1798–805. doi: 10.1016/j.ejrad.2011.04.028 Hoang JK Vanka J Ludwig BJ Glastonbury CM . Evaluation of cervical lymph nodes in head and neck cancer with CT and MRI: tips, traps, and a systematic approach. AJR Am J Roentgenol. (2013) 200:W17–25. doi: 10.2214/AJR.12.8960 Zhang C B-j L Liu Z Wang L-L Cheng W . Predicting the factors associated with central lymph node metastasis in clinical node-negative (cN0) papillary thyroid microcarcinoma. Eur Arch Oto Rhino Laryngol. (2020) 277:1191–8. doi: 10.1007/s00405-020-05787-1 Park JP Roh J-L Lee JH Baek JH Gong G Cho K-J . Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma. Am J Surg. (2014) 208:412–8. doi: 10.1016/j.amjsurg.2013.10.032 Du J Yang Q Sun Y Shi P Xu H Chen X . Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study. Front Endocrinol (Lausanne). (2023) 14:1288527. doi: 10.3389/fendo.2023.1288527 Zhu F Shen YB Li FQ Fang Y Hu L Wu YJ . The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma. Medicine. (2016) 95:e2674. doi: 10.1097/MD.0000000000002674 So YK Kim M-J Kim S Son Y-I . Lateral lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis for prevalence, risk factors, and location. Int J Surg. (2018) 50:94–103. doi: 10.1016/j.ijsu.2017.12.029 Zhao H Huang T Li H . Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer. Surgery. (2019) 166:55–60. doi: 10.1016/j.surg.2019.01.025 Shao L Wang Z Dong W Sun W Zhang H . Risk factors associated with preferential lateral lymph node metastasis in papillary thyroid carcinoma. Cancer Med. (2023) 12:20670–6. doi: 10.1002/cam4.v12.22 Wu C Wang L Chen W Zou S Yang A . Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer. Medicine. (2017) 96:e6202. doi: 10.1097/MD.0000000000006202 Popadich A Levin O Lee JC Smooke-Praw S Ro K Fazel M . A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. (2011) 150:1048–57. doi: 10.1016/j.surg.2011.09.003 Lang BH Ng SH Lau LL Cowling BJ Wong KP Wan KY . A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid. (2013) 23:1087–98. doi: 10.1089/thy.2012.0608